MECHANISMS OF THE INFLUENCE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ON LDL RECEPTOR FUNCTION AND CARDIOVASCULAR RISK IN TYPE 2 DM (literature review)

In the modern world, prevalence of dysmetabolic conditions, which are accompanied by corruption lipid metabolism and distribution adipose tissue in body, is increasing, their consequences include cardiovascular diseases, type 2 diabetes mellitus (T2DM) etc. These pathologies characterized dyslipidemia, reflects an imbalance processes assimilation, transportation, absorption use fatty acids’ cells as energy plastic substrates. A decrease relative content unsaturated acids low-density lipoproteins (LDL) causes dysfunction cell membranes, increase serum concentration LDL means cells, contributes to development atherosclerosis. Absorption occurs through interaction apolipoprotein apoE/B-100 with membrane receptor LDL. The regulates supply lipids cholesterol synthesizing these receptors. expression receptors regulated at level transcription; particularly, it stimulated insulin suppressed excess cholesterol, latter leading abnormal accumulation tissues pathology various organs. According clinical experimental studies meta-analyses, drugs from group inhibitors sodium-dependent glucose cotransporter-2 (SGLT2) have a pronounced protective cardiorenal effect patients T2DM cases kidney heart dysfunction. beneficial effects associated improving sensitivity, increasing antiatherogenic HDL reducing visceral fat, stimulating lipolysis, switching oxidation towards preferential paradoxical mainly due less atherogenic large floating particles, negative apparently counterweight wide range pleiotropic gliflozins.